The impact of postoperative adjuvant therapy on EGFR-mutated stage IA lung adenocarcinoma with micropapillary pathological subtypes
MPP was related to earlier recurrence and shortened survival time, even in stage IA. Further research needs a larger sample size to clarify that EGFR-mutated stage IA patients with MPP components obtain survival benefits from adjuvant therapy.
Authors
- Ran Cheng (ORCID: https://orcid.org/0000-0001-9410-8263)
- Jianfu Li (ORCID: https://orcid.org/0009-0003-6301-803X)
- Qiu Li (ORCID: https://orcid.org/0000-0002-5299-9050)
- Wentao Wu (ORCID: https://orcid.org/0000-0001-7621-2198)
- Kaiwen Ye
- Yaowen Zhang (ORCID: https://orcid.org/0000-0003-4218-5771)
- Zhenhui Zhang
- Xiang Zheng
- Jun Liu
- Jianzhao Xian
- Zhexue Hao
- Sihe Huang
- Haoyang Huang
Institutions
- Henan University (CN)
- First Affiliated Hospital of Guangzhou Medical University (CN)
- State Key Laboratory of Respiratory Disease (CN)
- Anyang Tumor Hospital (CN)
- Guangzhou Medical University (CN)
Publication Details
- Journal
- World Journal of Surgical Oncology
- Published
- 2024-09-05
- DOI
- https://doi.org/10.1186/s12957-024-03429-y
- Citations
- 1
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.42